{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,2]],"date-time":"2026-01-02T13:45:05Z","timestamp":1767361505988,"version":"3.48.0"},"reference-count":52,"publisher":"Informa UK Limited","issue":"1","license":[{"start":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T00:00:00Z","timestamp":1765756800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004328","name":"Genentech, Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004328","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Future Oncology"],"published-print":{"date-parts":[[2026,1,2]]},"DOI":"10.1080\/14796694.2025.2595690","type":"journal-article","created":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T10:34:12Z","timestamp":1765794852000},"page":"59-69","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":0,"title":["Impact of community recruitment and inclusion initiatives on enrollment in the biomarker-driven MyTACTIC trial"],"prefix":"10.1080","volume":"22","author":[{"given":"Richard M.","family":"Zuniga","sequence":"first","affiliation":[{"name":"OneOncology, Inc","place":["Nashville, USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ari","family":"VanderWalde","sequence":"additional","affiliation":[{"name":"West Cancer Center and Research Institute","place":["Germantown, USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lee S.","family":"Schwartzberg","sequence":"additional","affiliation":[{"name":"Pennington Cancer Institute, Renown Health","place":["Reno, USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David R.","family":"Spigel","sequence":"additional","affiliation":[{"name":"Tennessee Oncology","place":["Nashville, USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luke","family":"Passler","sequence":"additional","affiliation":[{"name":"Genentech, Inc","place":["South San Francisco, USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jason","family":"Hong","sequence":"additional","affiliation":[{"name":"Genentech, Inc","place":["South San Francisco, USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Howland","sequence":"additional","affiliation":[{"name":"Genentech, Inc","place":["South San Francisco, USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Walter C.","family":"Darbonne","sequence":"additional","affiliation":[{"name":"Genentech, Inc","place":["South San Francisco, USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tania","family":"Szado","sequence":"additional","affiliation":[{"name":"Genentech, Inc","place":["South San Francisco, USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Davey","family":"Daniel","sequence":"additional","affiliation":[{"name":"OneOncology, Inc","place":["Nashville, USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2025,12,15]]},"reference":[{"key":"e_1_3_9_3_1","doi-asserted-by":"publisher","DOI":"10.1097\/coc.0000000000000725"},{"key":"e_1_3_9_4_1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djy221"},{"key":"e_1_3_9_5_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.2832"},{"key":"e_1_3_9_6_1","unstructured":"U.S. Food and Drug Administration [Internet]. 2015\u20132019: drug trials snapshots summary report - five-year summary and analysis of clinical trial participation and demographics. 2020 [cited 2024 May 29]. Available from: https:\/\/web.archive.org\/web\/20230912063628\/"},{"key":"e_1_3_9_7_1","unstructured":"U.S. Food and Drugs Adminstration [Internet]. Enhancing the diversity of clinical trial populations \u2014 eligibility criteria enrollment practices and trial designs guidance for industry. 2020 [cited 2024 May 29]. Available from: https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/enhancing-diversity-clinical-trial-populations-eligibility-criteria-enrollment-practices-and-trial"},{"key":"e_1_3_9_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/jcpt.13532"},{"key":"e_1_3_9_9_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-021-00316-8"},{"key":"e_1_3_9_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jnma.2022.01.004"},{"key":"e_1_3_9_11_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.291.22.2720"},{"key":"e_1_3_9_12_1","doi-asserted-by":"publisher","DOI":"10.1200\/jop.2017.025288"},{"key":"e_1_3_9_13_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.33205"},{"key":"e_1_3_9_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/0197-2456(95)00048-8"},{"key":"e_1_3_9_15_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2021.06.079"},{"key":"e_1_3_9_16_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.32755"},{"key":"e_1_3_9_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.15242"},{"key":"e_1_3_9_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cct.2023.107416"},{"key":"e_1_3_9_19_1","unstructured":"Genentech. Advancing inclusive research\u00ae. 2025 Available from: https:\/\/www.gene.com\/patients\/clinical-trials\/advancing-inclusive-research"},{"key":"e_1_3_9_20_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2021.39.15_suppl.TPS1588"},{"key":"e_1_3_9_21_1","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.Am2022-ct128"},{"key":"e_1_3_9_22_1","doi-asserted-by":"publisher","DOI":"10.1053\/lc.1999.v133.a94931"},{"key":"e_1_3_9_23_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2010.02.337"},{"key":"e_1_3_9_24_1","doi-asserted-by":"publisher","DOI":"10.1159\/000180580"},{"key":"e_1_3_9_25_1","unstructured":"U.S. Food and Drug Administration. Cancer clinical trial eligibility criteria: patients with HIV hepatitis B virus or hepatitis C virus infections - guidance for industry. U.S. Department of Health and Human Services; 2020 [cited 2024 May 29]; Available from: https:\/\/www.fda.gov\/media\/121319\/download"},{"key":"e_1_3_9_26_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-021-03430-5"},{"key":"e_1_3_9_27_1","unstructured":"U.S. National Institutes of Health (NIH). State cancer profiles. Source: National Program of Cancer Registries SEER*Stat database - United States Department of Health and Human Services Centers for Disease Control and Prevention. 2024 [cited 2024 Jan]. Available from: http:\/\/www.statecancerprofiles.cancer.gov\/incidencerates\/index.php"},{"key":"e_1_3_9_28_1","unstructured":"U.S. National Institutes of Health (NIH). State cancer profiles. Source: SEER November 2022 submission 2024. [cited 2024 May]. Available from: https:\/\/www.statecancerprofiles.cancer.gov\/incidencerates\/index.php"},{"key":"e_1_3_9_29_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.01030"},{"key":"e_1_3_9_30_1","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2007.0067"},{"key":"e_1_3_9_31_1","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2001.19.6.1728"},{"key":"e_1_3_9_32_1","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2011-0384"},{"key":"e_1_3_9_33_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11606-022-07801-0"},{"key":"e_1_3_9_34_1","doi-asserted-by":"publisher","DOI":"10.1177\/107327481602300404"},{"key":"e_1_3_9_35_1","doi-asserted-by":"publisher","DOI":"10.4103\/picr.PICR_6_20"},{"key":"e_1_3_9_36_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41746-022-00581-1"},{"key":"e_1_3_9_37_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41746-020-0302-y"},{"key":"e_1_3_9_38_1","doi-asserted-by":"publisher","DOI":"10.1161\/circulationaha.119.040798"},{"key":"e_1_3_9_39_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0171315"},{"key":"e_1_3_9_40_1","doi-asserted-by":"publisher","DOI":"10.1111\/dme.13979"},{"key":"e_1_3_9_41_1","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2011-1894"},{"key":"e_1_3_9_42_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdiacomp.2022.108229"},{"key":"e_1_3_9_43_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.oret.2023.07.015"},{"key":"e_1_3_9_44_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc15-2686"},{"key":"e_1_3_9_45_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11892-013-0421-9"},{"key":"e_1_3_9_46_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjdrc-2021-002176"},{"key":"e_1_3_9_47_1","doi-asserted-by":"publisher","DOI":"10.1016\/s1098-3597(06)80053-0"},{"key":"e_1_3_9_48_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.24.3881"},{"key":"e_1_3_9_49_1","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.30925"},{"key":"e_1_3_9_50_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2020.08.1916"},{"key":"e_1_3_9_51_1","unstructured":"National Kidney Foundation [Internet]. Race ethnicity & kidney disease. 2020 [cited 2024 May 29]. Available from: https:\/\/www.kidney.org\/atoz\/content\/minorities-KD"},{"key":"e_1_3_9_52_1","unstructured":"U.S. Food and Drug Administration. Diversity action plans to improve enrollment of participants from underrepresented populations in clinical studies. 2024 [cited 2025 Aug 1]. Available from: https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/diversity-action-plans-improve-enrollment-participants-underrepresented-populations-clinical-studies"},{"key":"e_1_3_9_53_1","doi-asserted-by":"publisher","DOI":"10.2105\/ajph.89.9.1322"},{"key":"e_1_3_9_54_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.h2147"}],"container-title":["Future Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14796694.2025.2595690","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,2]],"date-time":"2026-01-02T13:40:50Z","timestamp":1767361250000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14796694.2025.2595690"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,15]]},"references-count":52,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1,2]]}},"alternative-id":["10.1080\/14796694.2025.2595690"],"URL":"https:\/\/doi.org\/10.1080\/14796694.2025.2595690","relation":{},"ISSN":["1479-6694","1744-8301"],"issn-type":[{"type":"print","value":"1479-6694"},{"type":"electronic","value":"1744-8301"}],"subject":[],"published":{"date-parts":[[2025,12,15]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifon20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifon20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2025-02-14","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-11-23","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-12-15","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}